PMID- 11948459
OWN - NLM
STAT- MEDLINE
DCOM- 20020501
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 98
IP  - 6
DP  - 2002 Apr 20
TI  - Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of 
      immunohistochemistry, fluorescence in situ hybridization and enzyme-linked 
      immuno-sorbent assay.
PG  - 833-7
AB  - c-erb-2 amplification and overexpression are currently attracting a great deal of 
      attention because a new adjuvant therapy using an antibody against the c-erbB-2 
      gene product, trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), 
      has proved effective in treating breast cancer with amplification and/or 
      overexpression of c-erbB-2. Aberrations of c-erbB-2 have also been detected in 
      ovarian, endometrial and gastric carcinomas at varied frequencies. Amplification 
      of the c-erbB-2 locus (17q12-q21.32), overexpression of c-erbB-2 protein (p185) 
      and serum levels of soluble c-erbB-2 protein fragments (p105) were examined in 
      gastric cancer patients using fluorescence in situ hybridization (FISH), 
      immunohistochemistry and enzyme-linked immunosorbent assay (ELISA), respectively. 
      Overexpression of c-erbB-2 protein was found in 29 (8.2%) of the 352 gastric 
      carcinomas analyzed. In FISH analysis, all tumors with 3+ immunostaining and 1 of 
      5 tumors with 2+ staining showed high-level amplification of c-erbB-2. 
      Pre-operative serum p105 was quantified in serum specimens from 129 patients with 
      gastric cancer and 28 patients with benign diseases. There were no significant 
      differences in the serum p105 levels among 11 patients with 
      c-erbB-2-overexpressing carcinomas, 118 patients with c-erbB-2 non-overexpressing 
      carcinomas and 28 controls, although a single case of gastric carcinoma 
      overexpressing c-erbB-2 with extensive liver metastasis had a higher level than 
      the cut-off value. The mechanisms of overexpression of p185 and high-level 
      amplification of c-erbB-2 in gastric adenocarcinomas seem similar to those 
      well-established in breast cancers. Patients having gastric adenocarcinoma with 
      c-erbB-2 amplification are potential candidates for a new adjuvant therapy using 
      humanized monoclonal antibody.
CI  - Copyright 2002 Wiley-Liss, Inc.
FAU - Takehana, Takuo
AU  - Takehana T
AD  - Department of Pathology, Yamanashi Medical University, Yamanashi, Japan.
FAU - Kunitomo, Kazuyoshi
AU  - Kunitomo K
FAU - Kono, Koji
AU  - Kono K
FAU - Kitahara, Fumiaki
AU  - Kitahara F
FAU - Iizuka, Hidehiko
AU  - Iizuka H
FAU - Matsumoto, Yoshiro
AU  - Matsumoto Y
FAU - Fujino, Masayuki A
AU  - Fujino MA
FAU - Ooi, Akishi
AU  - Ooi A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/genetics/*metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosomes, Human, Pair 17
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Stomach Neoplasms/genetics/*metabolism
EDAT- 2002/04/12 10:00
MHDA- 2002/05/02 10:01
CRDT- 2002/04/12 10:00
PHST- 2002/04/12 10:00 [pubmed]
PHST- 2002/05/02 10:01 [medline]
PHST- 2002/04/12 10:00 [entrez]
AID - 10.1002/ijc.10257 [pii]
AID - 10.1002/ijc.10257 [doi]
PST - ppublish
SO  - Int J Cancer. 2002 Apr 20;98(6):833-7. doi: 10.1002/ijc.10257.